Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger R

Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a mes

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “

U.S. stock futures rose, while National Beverage and several stocks fell premarket after disappointi

Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2

Hsbc Holdings PLC acquired a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:

BlackRock Inc. bought a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT)

Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regu

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “

After reaching an important support level, Arcturus Therapeutics Holdings Inc. (ARCT) could be a goo

Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's

Elon Musk said mRNA could fundamentally change disease treatment, turning medicine into a software p

Gainers Tenon Medical (NASDAQ:TNON) stock rose 122.5% to $12.13 during Wednesday's pre-market s

Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.84 per share versus the Zacks Cons

Arcturus Therapeutics NASDAQ: ARCT reported progress across its rare-disease pipeline during the sec

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.84) per share which beat the an

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “

Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) and Arcturus Therapeutics (NASDAQ: ARCT - Get Free

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) has been given a consensus reco

Amova Asset Management Americas Inc. grew its holdings in shares of Arcturus Therapeutics Holdings I

Webcast link can be found under Investor Relations/Events section of Arcturus’ website.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “

Arcturus has dropped off enough to make it a net-cash stock - a stock trading for less its current a

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being high

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is collaborating with Thermo Fisher Scientific Inc

Arcturus partners with Thermo Fisher to support Phase 3 development and potential commercialization

Top analysts upgraded Palantir, Silicom, Adobe, and Chevron. See what other analysts think about the

Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. Consid

Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing righ

Freedom Broker analyst Ilya Zubkov initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.95) per share which beat the an

Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings pag

Wall Street analysts upgraded top stocks, including Chipotle, ARM, BP, and Solaredge. See what they

Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy

Top Wall Street analysts upgraded Carnival Corp, Tandem Diabetes Care, and Union Pacific Corp. Analy

Wall Street analysts have changed their outlook on top names, with new coverage and price targets. S

B. Riley Securities analyst Mayank Mamtani initiates coverage on Arcturus Therapeutics (NASDAQ:AR

Citigroup analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lower

Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral

Piper Sandler analyst Yasmeen Rahimi maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Overwei

Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral